Avacta Group Announces Positive Preclinical Data for AVA6103

Avacta Group plc reported positive preclinical data for its peptide-drug conjugate, AVA6103, showing superior tumor response and disease control compared to Enhertu in models of Enhertu-resistant HER2+/FAP+ gastric tumors. This data underscores the potential of Avacta's proprietary pre|CISION platform in developing targeted cancer therapies and addressing resistance in difficult tumor types.